{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T08:35:04Z","timestamp":1783499704270,"version":"3.55.0"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2015,2,6]],"date-time":"2015-02-06T00:00:00Z","timestamp":1423180800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Transl Med"],"published-print":{"date-parts":[[2015,12]]},"DOI":"10.1186\/s12967-015-0415-2","type":"journal-article","created":{"date-parts":[[2015,2,5]],"date-time":"2015-02-05T17:38:36Z","timestamp":1423157916000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":63,"title":["A chimeric EBV gp350\/220-based VLP replicates the virion B-cell attachment mechanism and elicits long-lasting neutralizing antibodies in mice"],"prefix":"10.1186","volume":"13","author":[{"given":"Javier Gordon","family":"Ogembo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew R","family":"Muraswki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lori W","family":"McGinnes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agapi","family":"Parcharidou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rujapak","family":"Sutiwisesak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timelia","family":"Tison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Avendano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deep","family":"Agnani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert W","family":"Finberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Trudy G","family":"Morrison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joyce D","family":"Fingeroth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,2,6]]},"reference":[{"key":"415_CR1","first-page":"2680","volume-title":"Fields Virology","author":"AB Rickinson","year":"2007","unstructured":"Rickinson AB, Kieff E. Epstein-Barr Virus. In: Knipe D, Howley P, editors. Fields Virology, vol. 2. 5th ed. Philadelphia: Lippincott Wilkins and Williams; 2007. p. 2680\u2013700. Epstein-Barr Virus.","edition":"5"},{"key":"415_CR2","volume-title":"The epidemiology of EBV and its association with malignant disease","author":"H Hjalgrim","year":"2007","unstructured":"Hjalgrim H, Friborg J, Melbye M. The epidemiology of EBV and its association with malignant disease. Cambridge: Cmbridge University Press; 2007."},{"key":"415_CR3","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1093\/infdis\/jis646","volume":"207","author":"HH Balfour Jr","year":"2013","unstructured":"Balfour Jr HH, Odumade OA, Schmeling DO, Mullan BD, Ed JA, Knight JA, et al. Behavioral, virologic, and immunologic factors associated with acquisition and severity of primary Epstein-Barr virus infection in university students. J Infect Dis. 2013;207:80\u20138.","journal-title":"J Infect Dis"},{"key":"415_CR4","doi-asserted-by":"publisher","first-page":"1993","DOI":"10.1056\/NEJMcp1001116","volume":"362","author":"K Luzuriaga","year":"2010","unstructured":"Luzuriaga K, Sullivan JL. Infectious mononucleosis. New England J Med. 2010;362:1993\u20132000.","journal-title":"New England J Med"},{"key":"415_CR5","first-page":"39","volume":"292","author":"DR Hochberg","year":"2005","unstructured":"Hochberg DR, Thorley-Lawson DA. Quantitative detection of viral gene expression in populations of Epstein-Barr virus-infected cells in vivo. Methods Mol Biol. 2005;292:39\u201356.","journal-title":"Methods Mol Biol"},{"key":"415_CR6","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1038\/nrclinonc.2014.31","volume":"11","author":"A Carbone","year":"2014","unstructured":"Carbone A, Vaccher E, Gloghini A, Pantanowitz L, Abayomi A, de Paoli P, et al. Diagnosis and management of lymphomas and other cancers in HIV-infected patients. Nat Rev Clin Oncol. 2014;11:223\u201338.","journal-title":"Nat Rev Clin Oncol"},{"key":"415_CR7","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1146\/annurev.med.56.082103.104727","volume":"56","author":"S Gottschalk","year":"2005","unstructured":"Gottschalk S, Rooney CM, Heslop HE. Post-transplant lymphoproliferative disorders. Annu Rev Med. 2005;56:29\u201344.","journal-title":"Annu Rev Med"},{"key":"415_CR8","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1111\/j.1399-3046.2005.00318.x","volume":"9","author":"UD Allen","year":"2005","unstructured":"Allen UD, Farkas G, Hebert D, Weitzman S, Stephens D, Petric M, et al. Risk factors for post-transplant lymphoproliferative disorder in pediatric patients: a case\u2013control study. Pediatr Transplant. 2005;9:450\u20135.","journal-title":"Pediatr Transplant"},{"key":"415_CR9","doi-asserted-by":"publisher","first-page":"1517","DOI":"10.1097\/00007890-199911270-00015","volume":"68","author":"C Paya","year":"1999","unstructured":"Paya C, Fung J, Nalesnik M, Kieff E, Green M, Gores G, et al. ASTS\/ASTP EBV-PTLD Task Force and The Mayo Clinic Organized International Consensus Development Meeting: Epstein-Barr virus-induced posttransplant lymphoproliferative disorders. Transplantation. 1999;68:1517\u201325.","journal-title":"Transplantation"},{"key":"415_CR10","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1146\/annurev.micro.112408.134019","volume":"64","author":"JT Schiller","year":"2010","unstructured":"Schiller JT, Lowy DR. Vaccines to prevent infections by oncoviruses. Annu Rev Microbiol. 2010;64:23\u201341.","journal-title":"Annu Rev Microbiol"},{"key":"415_CR11","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1016\/j.coi.2010.11.009","volume":"23","author":"K Kwak","year":"2011","unstructured":"Kwak K, Yemelyanova A, Roden RB. Prevention of cancer by prophylactic human papillomavirus vaccines. Curr Opin Immunol. 2011;23:244\u201351.","journal-title":"Curr Opin Immunol"},{"key":"415_CR12","doi-asserted-by":"publisher","first-page":"5307","DOI":"10.1073\/pnas.77.9.5307","volume":"77","author":"DA Thorley-Lawson","year":"1980","unstructured":"Thorley-Lawson DA, Geilinger K. Monoclonal antibodies against the major glycoprotein (gp350\/220) of Epstein-Barr virus neutralize infectivity. Proc Natl Acad Sci U S A. 1980;77:5307\u201311.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"415_CR13","doi-asserted-by":"publisher","first-page":"4510","DOI":"10.1073\/pnas.81.14.4510","volume":"81","author":"JD Fingeroth","year":"1984","unstructured":"Fingeroth JD, Weis JJ, Tedder TF, Strominger JL, Biro PA, Fearon DT. Epstein-Barr virus receptor of human B lymphocytes is the C3d receptor CR2. Proc Natl Acad Sci U S A. 1984;81:4510\u20134.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"415_CR14","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1016\/j.celrep.2013.01.023","volume":"3","author":"JG Ogembo","year":"2013","unstructured":"Ogembo JG, Kannan L, Ghiran I, Nicholson-Weller A, Finberg RW, Tsokos GC, et al. Human complement receptor type 1\/CD35 is an Epstein-Barr Virus receptor. Cell Rep. 2013;3:371\u201385.","journal-title":"Cell Rep"},{"key":"415_CR15","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/0092-8674(87)90216-9","volume":"50","author":"J Tanner","year":"1987","unstructured":"Tanner J, Weis J, Fearon D, Whang Y, Kieff E. Epstein-Barr virus gp350\/220 binding to the B lymphocyte C3d receptor mediates adsorption, capping, and endocytosis. Cell. 1987;50:203\u201313.","journal-title":"Cell"},{"key":"415_CR16","doi-asserted-by":"publisher","first-page":"107fs107","DOI":"10.1126\/scitranslmed.3002878","volume":"3","author":"JI Cohen","year":"2011","unstructured":"Cohen JI, Fauci AS, Varmus H, Nabel GJ. Epstein-Barr virus: an important vaccine target for cancer prevention. Sci Transl Med. 2011;3:107fs107.","journal-title":"Sci Transl Med"},{"key":"415_CR17","doi-asserted-by":"publisher","first-page":"1749","DOI":"10.1086\/523813","volume":"196","author":"EM Sokal","year":"2007","unstructured":"Sokal EM, Hoppenbrouwers K, Vandermeulen C, Moutschen M, L\u00e9onard P, Moreels A, et al. Recombinant gp350 vaccine for infectious mononucleosis: a phase 2, randomized, double-blind, placebo-controlled trial to evaluate the safety, immunogenicity, and efficacy of an Epstein-Barr virus vaccine in healthy young adults. J Infect Dis. 2007;196:1749\u201353.","journal-title":"J Infect Dis"},{"key":"415_CR18","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1016\/0264-410X(88)90174-0","volume":"6","author":"SM Kingsman","year":"1988","unstructured":"Kingsman SM, Kingsman AJ. Polyvalent recombinant antigens: a new vaccine strategy. Vaccine. 1988;6:304\u20136.","journal-title":"Vaccine"},{"key":"415_CR19","doi-asserted-by":"publisher","first-page":"3724","DOI":"10.4049\/jimmunol.1103312","volume":"188","author":"A Link","year":"2012","unstructured":"Link A, Zabel F, Schnetzler Y, Titz A, Brombacher F, Bachmann MF. Innate immunity mediates follicular transport of particulate but not soluble protein antigen. J Immunol. 2012;188:3724\u201333.","journal-title":"J Immunol"},{"key":"415_CR20","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1586\/14760584.6.3.381","volume":"6","author":"B Chackerian","year":"2007","unstructured":"Chackerian B. Virus-like particles: flexible platforms for vaccine development. Expert Rev Vaccines. 2007;6:381\u201390.","journal-title":"Expert Rev Vaccines"},{"key":"415_CR21","doi-asserted-by":"publisher","first-page":"2011","DOI":"10.1128\/JVI.02533-12","volume":"87","author":"S Pavlova","year":"2013","unstructured":"Pavlova S, Feederle R, Gartner K, Fuchs W, Granzow H, Delecluse HJ. An Epstein-Barr virus mutant produces immunogenic defective particles devoid of viral DNA. J Virol. 2013;87:2011\u201322.","journal-title":"J Virol"},{"key":"415_CR22","doi-asserted-by":"publisher","first-page":"13105","DOI":"10.1128\/JVI.05598-11","volume":"85","author":"R Ruiss","year":"2011","unstructured":"Ruiss R, Jochum S, Wanner G, Reisbach G, Hammerschmidt W, Zeidler R. A virus-like particle-based Epstein-Barr virus vaccine. J Virol. 2011;85:13105\u201313.","journal-title":"J Virol"},{"key":"415_CR23","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1007\/s007050050574","volume":"144","author":"P Speck","year":"1999","unstructured":"Speck P, Longnecker R. Epstein-Barr virus (EBV) infection visualized by EGFP expression demonstrates dependence on known mediators of EBV entry. Arch Virol. 1999;144:1123\u201337.","journal-title":"Arch Virol"},{"key":"415_CR24","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1002\/j.1460-2075.1984.tb01933.x","volume":"3","author":"M Biggin","year":"1984","unstructured":"Biggin M, Farrell PJ, Barrell BG. Transcription and DNA sequence of the BamHI L fragment of B95-8 Epstein-Barr virus. EMBO J. 1984;3:1083\u201390.","journal-title":"EMBO J"},{"key":"415_CR25","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1016\/0378-1119(89)90209-6","volume":"79","author":"M Jun-ichi","year":"1989","unstructured":"Jun-ichi M, Satoshi T, Kimi A, Fumi T, Akira T, Kiyoshi T, et al. Expression vector system based on the chicken \u03b2-actin promoter directs efficient production of interleukin-5. Gene. 1989;79:269\u201377.","journal-title":"Gene"},{"key":"415_CR26","doi-asserted-by":"publisher","first-page":"11062","DOI":"10.1128\/JVI.00726-06","volume":"80","author":"HD Pantua","year":"2006","unstructured":"Pantua HD, McGinnes LW, Peeples ME, Morrison TG. Requirements for the assembly and release of Newcastle disease virus-like particles. J Virolol. 2006;80:11062\u201373.","journal-title":"J Virolol"},{"key":"415_CR27","first-page":"11","volume":"18.12","author":"LW McGinnes","year":"2013","unstructured":"McGinnes LW, Morrison TG. Newcastle disease virus\u2010like particles: preparation, purification, quantification, and incorporation of foreign glycoproteins. Curr Protoc Microbiol. 2013;18.12:11\u20138. 12. 21.","journal-title":"Curr Protoc Microbiol"},{"key":"415_CR28","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1186\/1472-6750-6-52","volume":"6","author":"C Muratori","year":"2006","unstructured":"Muratori C, D\u2019Aloja P, Superti F, Tinari A, Sol-Foulon N, Sparacio S, et al. Generation and characterization of a stable cell population releasing fluorescent HIV-1-based Virus Like Particles in an inducible way. BMC Biotechnol. 2006;6:52.","journal-title":"BMC Biotechnol"},{"key":"415_CR29","doi-asserted-by":"publisher","first-page":"1951","DOI":"10.1128\/JVI.77.3.1951-1963.2003","volume":"77","author":"LW McGinnes","year":"2003","unstructured":"McGinnes LW, Reitter JN, Gravel K, Morrison TG. Evidence for mixed membrane topology of the newcastle disease virus fusion protein. J Virolol. 2003;77:1951\u201363.","journal-title":"J Virolol"},{"key":"415_CR30","doi-asserted-by":"publisher","first-page":"13996","DOI":"10.1073\/pnas.1210275109","volume":"109","author":"AJ Battisti","year":"2012","unstructured":"Battisti AJ, Meng G, Winkler DC, McGinnes LW, Plevka P, Steven AC, et al. Structure and assembly of a paramyxovirus matrix protein. Proc Natl Acad Sci. 2012;109:13996\u20134000.","journal-title":"Proc Natl Acad Sci"},{"key":"415_CR31","doi-asserted-by":"publisher","first-page":"3465","DOI":"10.1182\/blood-2008-04-151845","volume":"112","author":"I Ghiran","year":"2008","unstructured":"Ghiran I, Glodek AM, Weaver G, Klickstein LB, Nicholson-Weller A. Ligation of erythrocyte CR1 induces its clustering in complex with scaffolding protein FAP-1. Blood. 2008;112:3465\u201373.","journal-title":"Blood"},{"key":"415_CR32","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.1128\/JVI.01709-09","volume":"84","author":"MR Murawski","year":"2010","unstructured":"Murawski MR, McGinnes LW, Finberg RW, Kurt-Jones EA, Massare MJ, Smith G, et al. Newcastle disease virus-like particles containing respiratory syncytial virus G protein induced protection in BALB\/c mice, with no evidence of immunopathology. J Virol. 2010;84:1110\u201323.","journal-title":"J Virol"},{"key":"415_CR33","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/j.virol.2009.06.013","volume":"391","author":"J Sashihara","year":"2009","unstructured":"Sashihara J, Burbelo PD, Savoldo B, Pierson TC, Cohen JI. Human antibody titers to Epstein-Barr Virus (EBV) gp350 correlate with neutralization of infectivity better than antibody titers to EBV gp42 using a rapid flow cytometry-based EBV neutralization assay. Virology. 2009;391:249\u201356.","journal-title":"Virology"},{"key":"415_CR34","doi-asserted-by":"publisher","first-page":"11660","DOI":"10.1128\/JVI.79.18.11660-11670.2005","volume":"79","author":"H Pantua","year":"2005","unstructured":"Pantua H, McGinnes LW, Leszyk J, Morrison TG. Characterization of an alternate form of Newcastle disease virus fusion protein. J Virol. 2005;79:11660\u201370.","journal-title":"J Virol"},{"key":"415_CR35","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1128\/JVI.01861-10","volume":"85","author":"LW McGinnes","year":"2011","unstructured":"McGinnes LW, Gravel KA, Finberg RW, Kurt-Jones EA, Massare MJ, Smith G, et al. Assembly and immunological properties of Newcastle disease virus-like particles containing the respiratory syncytial virus F and G proteins. J Virol. 2011;85:366\u201377.","journal-title":"J Virol"},{"key":"415_CR36","doi-asserted-by":"crossref","first-page":"4452","DOI":"10.1128\/jvi.62.12.4452-4464.1988","volume":"62","author":"J Tanner","year":"1988","unstructured":"Tanner J, Whang Y, Sample J, Sears A, Kieff E. Soluble gp350\/220 and deletion mutant glycoproteins block Epstein-Barr virus adsorption to lymphocytes. J Virol. 1988;62:4452\u201364.","journal-title":"J Virol"},{"key":"415_CR37","doi-asserted-by":"publisher","first-page":"1769","DOI":"10.1099\/vir.0.043265-0","volume":"93","author":"R Germi","year":"2012","unstructured":"Germi R, Effantin G, Grossi L, Ruigrok RW, Morand P, Schoehn G. Three-dimensional structure of the Epstein\u2013Barr virus capsid. J Gen Virol. 2012;93:1769\u201373.","journal-title":"J Gen Virol"},{"key":"415_CR38","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1002\/eji.201142064","volume":"42","author":"M Braun","year":"2012","unstructured":"Braun M, Jandus C, Maurer P, Hammann-Haenni A, Schwarz K, Bachmann MF, et al. Virus-like particles induce robust human T-helper cell responses. Eur J Immunol. 2012;42:330\u201340.","journal-title":"Eur J Immunol"},{"key":"415_CR39","doi-asserted-by":"publisher","first-page":"2725","DOI":"10.4155\/bio.12.239","volume":"4","author":"F Civoli","year":"2012","unstructured":"Civoli F, Kroenke MA, Reynhardt K, Zhuang Y, Kaliyaperumal A, Gupta S. Development and optimization of neutralizing antibody assays to monitor clinical immunogenicity. Bioanalysis. 2012;4:2725\u201335.","journal-title":"Bioanalysis"},{"key":"415_CR40","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1093\/jnci\/56.4.697","volume":"56","author":"MA Epstein","year":"1976","unstructured":"Epstein MA. Epstein-Barr virus\u2013is it time to develop a vaccine program? J Natl Cancer Inst. 1976;56:697\u2013700.","journal-title":"J Natl Cancer Inst"},{"key":"415_CR41","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1016\/j.virol.2005.09.020","volume":"344","author":"T Dudek","year":"2006","unstructured":"Dudek T, Knipe DM. Replication-defective viruses as vaccines and vaccine vectors. Virology. 2006;344:230\u20139.","journal-title":"Virology"},{"key":"415_CR42","doi-asserted-by":"publisher","first-page":"12","DOI":"10.2174\/1874357901206010012","volume":"6","author":"H Mok","year":"2012","unstructured":"Mok H, Cheng X, Xu Q, Zengel JR, Parhy B, Zhao J, et al. Evaluation of measles vaccine virus as a vector to deliver respiratory syncytial virus fusion protein or Epstein-Barr virus glycoprotein gp350. Open Virol J. 2012;6:12.","journal-title":"Open Virol J"},{"key":"415_CR43","doi-asserted-by":"publisher","first-page":"5009","DOI":"10.1158\/1078-0432.CCR-14-1122-T","volume":"20","author":"GS Taylor","year":"2014","unstructured":"Taylor GS, Jia H, Harrington K, Lee LW, Turner J, Ladell K, et al. A recombinant modified vaccinia Ankara vaccine encoding Epstein-Barr Virus (EBV) target antigens: a phase I trial in UK patients with EBV-positive cancer. Clin Cancer Res. 2014;20:5009\u201322.","journal-title":"Clin Cancer Res"},{"key":"415_CR44","doi-asserted-by":"publisher","first-page":"3877","DOI":"10.1128\/JVI.01733-08","volume":"83","author":"BW Henson","year":"2009","unstructured":"Henson BW, Perkins EM, Cothran JE, Desai P. Self-assembly of Epstein-Barr virus capsids. J Virol. 2009;83:3877\u201390.","journal-title":"J Virol"},{"key":"415_CR45","doi-asserted-by":"publisher","first-page":"3039","DOI":"10.1016\/j.vaccine.2013.04.071","volume":"31","author":"X Cui","year":"2013","unstructured":"Cui X, Cao Z, Sen G, Chattopadhyay G, Fuller DH, Fuller JT, et al. A novel tetrameric gp350 1\u2013470 as a potential Epstein-Barr virus vaccine. Vaccine. 2013;31:3039\u201345.","journal-title":"Vaccine"},{"key":"415_CR46","doi-asserted-by":"publisher","first-page":"4697","DOI":"10.1016\/j.vaccine.2007.04.008","volume":"25","author":"M Moutschen","year":"2007","unstructured":"Moutschen M, Leonard P, Sokal EM, Smets F, Haumont M, Mazzu P, et al. Phase I\/II studies to evaluate safety and immunogenicity of a recombinant gp350 Epstein-Barr virus vaccine in healthy adults. Vaccine. 2007;25:4697\u2013705.","journal-title":"Vaccine"},{"key":"415_CR47","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1097\/TP.0b013e3181b9d918","volume":"88","author":"L Rees","year":"2009","unstructured":"Rees L, Tizard EJ, Morgan AJ, Cubitt WD, Finerty S, Oyewole-Eletu TA, et al. A phase I trial of epstein-barr virus gp350 vaccine for children with chronic kidney disease awaiting transplantation. Transplantation. 2009;88:1025\u20139.","journal-title":"Transplantation"},{"key":"415_CR48","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1038\/nbt0706-769","volume":"24","author":"G Walsh","year":"2006","unstructured":"Walsh G. Biopharmaceutical benchmarks 2006. Nat Biotechnol. 2006;24:769\u201376.","journal-title":"Nat Biotechnol"},{"key":"415_CR49","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/S0167-7799(99)01420-1","volume":"18","author":"F Hesse","year":"2000","unstructured":"Hesse F, Wagner R. Developments and improvements in the manufacturing of human therapeutics with mammalian cell cultures. Trends Biotechnol. 2000;18:173\u201380.","journal-title":"Trends Biotechnol"},{"key":"415_CR50","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.jim.2014.04.009","volume":"410","author":"B Chatterjee","year":"2014","unstructured":"Chatterjee B, Leung CS, M\u00fcnz C. Animal models of Epstein Barr virus infection. J Immunol Methods. 2014;410:80\u20137.","journal-title":"J Immunol Methods"},{"key":"415_CR51","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1086\/590502","volume":"198","author":"M Yajima","year":"2008","unstructured":"Yajima M, Imadome K, Nakagawa A, Watanabe S, Terashima K, Nakamura H, et al. A new humanized mouse model of Epstein-Barr virus infection that reproduces persistent infection, lymphoproliferative disorder, and cell-mediated and humoral immune responses. J Infect Dis. 2008;198:673\u201382.","journal-title":"J Infect Dis"},{"key":"415_CR52","doi-asserted-by":"publisher","first-page":"12180","DOI":"10.1073\/pnas.89.24.12180","volume":"89","author":"R Kirnbauer","year":"1992","unstructured":"Kirnbauer R, Booy F, Cheng N, Lowy DR, Schiller JT. Papillomavirus L1 major capsid protein self-assembles into virus-like particles that are highly immunogenic. Proc Natl Acad Sci U S A. 1992;89:12180\u20134.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"415_CR53","doi-asserted-by":"publisher","first-page":"1645","DOI":"10.1056\/NEJMoa020586","volume":"347","author":"LA Koutsky","year":"2002","unstructured":"Koutsky LA, Ault KA, Wheeler CM, Brown DR, Barr E, Alvarez FB, et al. A controlled trial of a human papillomavirus type 16 vaccine. N Engl J Med. 2002;347:1645\u201351.","journal-title":"N Engl J Med"}],"container-title":["Journal of Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-015-0415-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12967-015-0415-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-015-0415-2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-015-0415-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,2]],"date-time":"2021-09-02T08:10:43Z","timestamp":1630570243000},"score":1,"resource":{"primary":{"URL":"https:\/\/translational-medicine.biomedcentral.com\/articles\/10.1186\/s12967-015-0415-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,2,6]]},"references-count":53,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015,12]]}},"alternative-id":["415"],"URL":"https:\/\/doi.org\/10.1186\/s12967-015-0415-2","relation":{},"ISSN":["1479-5876"],"issn-type":[{"value":"1479-5876","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,2,6]]},"assertion":[{"value":"1 December 2014","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 January 2015","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 February 2015","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"50"}}